Adherex adds three sites to its phase 2 trial of ADH-1 in tumors

By Lisa Kerner

Erie, Pa., March 2 - Adherex Technologies Inc. said it has added three Canadian sites to its phase 2 clinical trial of ADH-1 (Exherin), bringing the total number of clinical trial sites to six.

"The increased number of centers involved in the phase 2 single-agent trial of ADH-1 will help ensure an even more robust accrual of patients, particularly in the less common tumor types, and expand the investigator base working with our drug," chairman and chief executive officer William P. Peters said in a company news release.

The phase 2 single-agent trial, currently ongoing at three sites in Canada, is designed to evaluate the antitumor activity and tolerability of repeated doses of ADH-1.

The company plans to enroll a total of 60 patients whose tumors express the molecular target N-cadherin.

Results from the trial are expected in the second half of 2006.

Adherex is a biopharmaceutical company based in Research Triangle Park, N.C., that discovers and develops novel cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.